Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: aminolevulinic acid HCL (ALA) Clear all
Completed Phase 3 Interventional Results available

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy

NCT00233402
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexvix, Standard white light cystoscopy
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 1 Interventional

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

NCT01148966
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
Interventions
aminolevulinic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer

NCT00052637
View directory record Official record
Conditions
Bladder Cancer
Interventions
hexaminolevulinate, biopsy, cystoscopy
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

NCT02560584
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate hydrochloride, KARL STORZ D-Light C PDD Flexible Videoscope System
Drug · Device
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Los Angeles, California • Chicago, Illinois • Iowa City, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 9, 2026, 4:02 AM EDT
Completed No phase listed Observational

Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas

NCT04055688
View directory record Official record
Conditions
Brain Tumor, Glioma
Interventions
Orbeye surgical videomicroscope, 5-Aminolevulinic Acid
Device · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Phase 1 Interventional

An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face

NCT07729579
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Investigational drug, Photodynamic therapy
Drug · Device
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain

NCT01116661
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevuline Acid (ALA)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 72 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses

NCT02124733
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic acid based photodynamic therapy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 3 Interventional Results available

Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease

NCT01525329
View directory record Official record
Conditions
Actinic Keratosis, Organ or Tissue Transplant; Complications
Interventions
5-Fluorouracil
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 9, 2026, 4:02 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Photodynamic Therapy for Cutibacterium Acnes (C. Acnes) Decolonization of the Shoulder Dermis

NCT04636242
View directory record Official record
Conditions
C. Acnes, Phototherapy, Postoperative Infection, Arthroscopic Rotator Cuff Repair, Shoulder Surgery
Interventions
Skin Biopsy, 5 Aminolevulinic Acid + Phototherapy
Procedure · Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

Fluorescence-guided Surgery for Low- and High-grade Gliomas

NCT01502280
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevulinic acid (ALA), Placebo - ascorbic acid
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 2 Interventional Results available

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

NCT05101798
View directory record Official record
Conditions
Neoplasm, Skull Base Neoplasm
Interventions
5-Aminolevulinic acid Hydrochloride
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

NCT02628236
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid (ALA), BLU-U
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional

Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis

NCT03022903
View directory record Official record
Conditions
Toenail Onychomycosis, Distal and Lateral Subungual Toenail Onychomycosis
Interventions
Aminolevulinic Acid (ALA)
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 9, 2026, 4:02 AM EDT
Not listed Phase 2 Interventional

A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT01403311
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevuline Acid
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

NCT05662202
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT00671710
View directory record Official record
Conditions
Brain Tumors
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
Advocate Hospital System
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2011 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

NCT06307548
View directory record Official record
Conditions
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
Interventions
Aminolevulinic Acid, Biospecimen Collection, Computed Tomography, Fluorescence-Guided Surgery, Magnetic Resonance Imaging, Photodynamic Therapy, Surgical Procedure
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

NCT02281136
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid (ALA), BLU-U
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Carmel, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

NCT06159842
View directory record Official record
Conditions
Facial Cutaneous Squamous Cell Carcinoma in Situ
Interventions
Aminolevulinic Acid 20% Topical Solution with Blue Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

NCT05060237
View directory record Official record
Conditions
Actinic Keratosis, Keratosis, Actinic, Keratosis
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 4 Interventional Results available

Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis

NCT02409732
View directory record Official record
Conditions
Actinic Cheilitis
Interventions
aminolevulinic acid hydrochloride, Photodynamic therapy with blue light
Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Photodynamic Therapy Incubation Times for Actinic Keratosis

NCT03066843
View directory record Official record
Conditions
Actinic Keratoses
Interventions
ALA (5-aminolevulinic acid), Blue light therapy
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Phase 2 Interventional

Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA

NCT06948552
View directory record Official record
Conditions
Upper Tract Urothelial Carcinoma
Interventions
5-Aminolevulinic acid Hydrochloride (Gliolan®)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 4:02 AM EDT